GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

NCT06522386 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Pirtobrutinib
DRUG: Rituximab
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]